Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04645459
Other study ID # N202004062
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 3, 2020
Est. completion date May 28, 2021

Study information

Verified date May 2020
Source Taipei Medical University
Contact Barbara Y.J. Chen
Phone +886963358528
Email d507103001@tmu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Consuming high levels of dietary phosphate and poor adherence of phosphate-binding-therapy might induce hyperphosphatemia in the hemodialysis (HD) patients. Therefore, the risks of Chronic Kidney Disease-related Mineral and Bone Disorders (CKD-MBDs) and inflammation will be increased. This double blind and intervention randomized controlled trial study will be designed to investigate the hypothesis that if low phosphorus meals decrease serum phosphorus concentration and inflammatory indicators. A total of 80 HD patients in the HD center of Shuang Ho Hospital will be recruited and be assigned to low phosphorus meal group (LP group) and control group randomly before one-week-washout period. The subjects of LP group and control group will consume low phosphorus meals and standard meals respectively. During washout period and study period, all subjects will continue to consume their regular breakfast and take one tablet of calcium carbonate with meal. All data will be collected at baseline, one week after the washout period, and the end of the 7-days-study period. The indicators are including dietary contents, phosphate binder administration, indicators of dialysis adequacy, nutritional indicators, blood lipid indicators, biochemical indicators, CKD-MBDs indicators, and inflammation indicators. Data were analyzed by Statistical Product and Service Solutions program version 18. Paired t-test, Student's t-test, Pearson correlation coefficient and Logistic regression will be used. P < 0.05 will be considered as statistically significant.


Description:

Study Design and Subjects: This study was design as a randomized, double-blind control trail. A total of 80 HD patients were recruited from the HD center of Taipei Medical University-Shuang Ho Hospital in Taiwan. The inclusion criteria were including ≧20 years old and non vegetarian. The exclusion criteria are including liver dysfunction, cancer and pregnancy. Dietary Intervention: All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week. For controlling the volumes of proteins, phosphorus and calcium easily, the main courses of both of the study and the control meals were made by a central kitchen. All of the meals contained 3 exchanges of protein (25 g) and 1 exchange of vegetable. There were 5 main courses for the both diets. The proteins of the study meals had been removed by an average 20 -30% of the phosphorus through boiling the meats before cooking process. But the boiling method did not process for the control meals. Every meal including all the study and the control meals contained one tablet of calcium carbonate. As a consequence, the additional phosphate binders should not be taken while eating the study meals. The subjects had to prepare carbohydrate by themselves, and they could choose any source of carbohydrate as their wants. Data Collection: The personal characteristics and the anthropometry data were collected at baseline. All data were collected at baseline, one week after the washout period, and the end of the 7-days-study period. The indicators were including dietary contents, phosphate binder administration, dialysis adequacy, nutritional indicators, blood lipid indicators, biochemical indicators, CKD-MBDs indicators, and inflammation indicators.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date May 28, 2021
Est. primary completion date May 28, 2021
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: - Hemodialysis patients, = 20 years of age Exclusion Criteria: - = 80 years of age, liver cirrhosis, cancer, pregnancy, vegetarian

Study Design


Related Conditions & MeSH terms


Intervention

Other:
low phosphorus meals
All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
control meals
All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.

Locations

Country Name City State
Taiwan Shuang Ho Hospital New Taipei City

Sponsors (1)

Lead Sponsor Collaborator
Taipei Medical University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary anthropometric measurement body height (cm) baseline
Primary anthropometric measurement body height (cm) one week after the washout period
Primary anthropometric measurement body height (cm) the end of the 7-days-study period
Primary anthropometric measurement body weight before hemodialysis (Kg), dry weight (Kg) baseline
Primary anthropometric measurement body weight before hemodialysis (Kg), dry weight (Kg) one week after the washout period
Primary anthropometric measurement body weight before hemodialysis (Kg), dry weight (Kg) the end of the 7-days-study period
Primary blood pressure systolic blood pressure (mmHg), diastolic blood pressure (mmHg) baseline
Primary blood pressure systolic blood pressure (mmHg), diastolic blood pressure (mmHg) one week after the washout period
Primary blood pressure systolic blood pressure (mmHg), diastolic blood pressure (mmHg) the end of the 7-days-study period
Primary dietary contents 24-hour dietary recall baseline
Primary dietary contents 24-hour dietary recall one week after the washout period
Primary dietary contents 24-hour dietary recall the end of the 7-days-study period
Primary phosphate binder administration type and dosing frequency baseline
Primary phosphate binder administration type and dosing frequency one week after the washout period
Primary phosphate binder administration type and dosing frequency the end of the 7-days-study period
Primary indicators of dialysis adequacy Kt/V baseline
Primary indicators of dialysis adequacy Kt/V one week after the washout period
Primary indicators of dialysis adequacy Kt/V the end of the 7-days-study period
Primary blood lipid indicators LDL(mg/dL), HDL (mg/dL) , cholesterol (mg/dL) , triglyceride (mg/dL) baseline
Primary blood lipid indicators LDL(mg/dL), HDL (mg/dL) , cholesterol (mg/dL) , triglyceride (mg/dL) one week after the washout period
Primary blood lipid indicators LDL(mg/dL), HDL (mg/dL) , cholesterol (mg/dL) , triglyceride (mg/dL) the end of the 7-days-study period
Primary biochemical indicators normalized protein equivalent of total nitrogen appearance(g/kg/d) baseline
Primary biochemical indicators normalized protein equivalent of total nitrogen appearance(g/kg/d) one week after the washout period
Primary biochemical indicators normalized protein equivalent of total nitrogen appearance(g/kg/d) the end of the 7-days-study period
Primary biochemical indicators pre-Alb(mg/dL) baseline
Primary biochemical indicators pre-Alb(mg/dL) one week after the washout period
Primary biochemical indicators pre-Alb(mg/dL) the end of the 7-days-study period
Primary biochemical indicators ferritin(ng/mL) baseline
Primary biochemical indicators ferritin(ng/mL) one week after the washout period
Primary biochemical indicators ferritin(ng/mL) the end of the 7-days-study period
Primary biochemical indicators red blood cell (10^6/µL), white blood count(10^3/µL) baseline
Primary biochemical indicators red blood cell (10^6/µL), white blood count(10^3/µL) one week after the washout period
Primary biochemical indicators red blood cell (10^6/µL), white blood count(10^3/µL) the end of the 7-days-study period
Primary biochemical indicators Hb (g/dL) baseline
Primary biochemical indicators Hb (g/dL) one week after the washout period
Primary biochemical indicators Hb (g/dL) the end of the 7-days-study period
Primary biochemical indicators Hct (%) baseline
Primary biochemical indicators Hct (%) one week after the washout period
Primary biochemical indicators Hct (%) the end of the 7-days-study period
Primary biochemical indicators FGF23 baseline
Primary biochemical indicators FGF23 one week after the washout period
Primary biochemical indicators FGF23 the end of the 7-days-study period
Primary biochemical indicators iPTH (pg/mL) baseline
Primary biochemical indicators iPTH (pg/mL) one week after the washout period
Primary biochemical indicators iPTH (pg/mL) the end of the 7-days-study period
Primary biochemical indicators blood urea nitrogen(mg/dL) , creatinine(mg/dL) , uric acid(mg/dL) baseline
Primary biochemical indicators blood urea nitrogen(mg/dL) , creatinine(mg/dL) , uric acid(mg/dL) one week after the washout period
Primary biochemical indicators blood urea nitrogen(mg/dL) , creatinine(mg/dL) , uric acid(mg/dL) the end of the 7-days-study period
Primary biochemical indicators estimated glomerular filtration rate (ml/min/1.73m^2) baseline
Primary biochemical indicators estimated glomerular filtration rate (ml/min/1.73m^2) one week after the washout period
Primary biochemical indicators estimated glomerular filtration rate (ml/min/1.73m^2) the end of the 7-days-study period
Primary inflammation indicators C reactive protein (mg/dL) baseline
Primary inflammation indicators C reactive protein (mg/dL) one week after the washout period
Primary inflammation indicators C reactive protein (mg/dL) the end of the 7-days-study period
Primary inflammation indicators interleukin-1 (pg/mL) , interleukin-6 (pg/mL) , tumor necrosis factor-a (pg/mL) baseline
Primary inflammation indicators interleukin-1 (pg/mL) , interleukin-6 (pg/mL) , tumor necrosis factor-a (pg/mL) one week after the washout period
Primary inflammation indicators interleukin-1 (pg/mL) , interleukin-6 (pg/mL) , tumor necrosis factor-a (pg/mL) the end of the 7-days-study period
Primary Electrolyte P(mg/dL), Ca(mg/dL), Mg(mg/dL) baseline
Primary Electrolyte P(mg/dL), Ca(mg/dL), Mg(mg/dL) one week after the washout period
Primary Electrolyte P(mg/dL), Ca(mg/dL), Mg(mg/dL) the end of the 7-days-study period
Primary Electrolyte K(mEq/L), Na(mEq/L) baseline
Primary Electrolyte K(mEq/L), Na(mEq/L) one week after the washout period
Primary Electrolyte K(mEq/L), Na(mEq/L) the end of the 7-days-study period
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06382701 - Effect of Aromatherapy on Pain, Anxiety and Satisfaction in Cannulation N/A
Completed NCT04674930 - Effects of Exercise Program on Physical Functioning of Hemodialysis Patients. N/A
Recruiting NCT02245633 - Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients N/A
Recruiting NCT01970280 - Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Phase 4
Completed NCT06165211 - Nature-Based Sound Application For Hemodialysis Patients N/A
Completed NCT05693584 - The Effect of Using Virtual Reality Glasses on Pain During Fistula Cannulation in Hemodialysis Patients N/A
Completed NCT06106763 - Mandala Colouring On Anxiety, Depression, Pain And Quality of Life N/A
Completed NCT01932853 - Association Between Dose Dialysis by Kt and Mortality N/A
Completed NCT01273974 - The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients Phase 2/Phase 3
Completed NCT04139759 - THE EFFECT OF HAND AND FOOT MASSAGE ON FATIGUE IN HEMODIALYSIS PATIENTS N/A
Not yet recruiting NCT05574595 - Effect on Pain and Comfort Associated With Fistula Puncture N/A
Completed NCT04175652 - Effects of Laughter Yoga on Hemodialysis Patients' Plasma-Beta Endorphin Levels, Pain Levels and Sleep Quality N/A
Not yet recruiting NCT06314243 - The Impact of Pumpkin Seed Oil Supplementation on Hemodialysis Patients Phase 3
Completed NCT01596842 - Effect of Omega-3 Fatty Acid on Vitamin D Activation Phase 4
Enrolling by invitation NCT01896882 - Dietary Sodium Restriction in Hemodialysis Patients N/A
Completed NCT00638300 - Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD) N/A
Terminated NCT00259714 - Dialysate Sodium Individualization in Hemodialysis Phase 1
Completed NCT01846754 - Prevalence of Fatigue in Hemodialysis Patients N/A
Completed NCT00491868 - Clinical Study of R744 to Hemodialysis Patients Phase 3
Completed NCT04195919 - The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients Phase 1